Last month, Scholar Rock achieved the primary endpoint in the company's own Phase 3 trial of apitegromab in SMA patients.
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.
Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and safety of its investigational muscle-targeted...
The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.14%. Stock indexes...
The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.03%. Stock indexes this...
The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.08%. Stock indexes this morning...
The market celebrated Scholar Rock's upsized stock offering and plans to advance development of a new obesity treatment. Here's what investors need to know.
Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today it...
Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role,...
Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that...